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Summary
 
We have shown previously that the inactivation of macrophages in nonobese diabetic (NOD)
mice results in the prevention of diabetes; however, the mechanisms involved remain un-
known. In this study, we found that T cells in a macrophage-depleted environment lost their
ability to differentiate into 
 
b
 
 cell–cytotoxic T cells, resulting in the prevention of autoimmune
diabetes, but these T cells regained their 
 
b
 
 cell–cytotoxic potential when returned to a mac-
rophage-containing environment. To learn why T cells in a macrophage-depleted environ-
ment lose their ability to kill 
 
b
 
 cells, we examined the islet antigen–specific immune response
and T cell activation in macrophage-depleted NOD mice. There was a shift in the immune
balance, a decrease in the T helper cell type 1 (Th1) immune response, and an increase in the
Th2 immune response, due to the reduced expression of the macrophage-derived cytokine
IL-12. As well, there was a deficit in T cell activation, evidenced by significant decreases in the
expression of Fas ligand and perforin. The administration of IL-12 substantially reversed the
prevention of diabetes in NOD mice conferred by macrophage depletion. We conclude that
macrophages play an essential role in the development and activation of 
 
b
 
 cell–cytotoxic T
cells that cause 
 
b
 
 cell destruction, resulting in autoimmune diabetes in NOD mice.
Key words: macrophages • T cells • T cell activation • nonobese diabetic mice • autoimmune 
diabetes
 
I
 
nsulin-dependent diabetes mellitus, also known as type I
diabetes, is a serious chronic childhood disorder caused
by the progressive loss of insulin-producing pancreatic 
 
b
 
cells, culminating in a state of hypoinsulinemia and hyper-
glycemia. Animal models used in the study of type I diabe-
tes, such as the BioBreeding (BB)
 
1
 
 rat and the nonobese di-
abetic (NOD) mouse, have enhanced our understanding of
the pathogenic mechanisms of this disease. The diabetic
syndrome in these animals results from the destruction of
pancreatic 
 
b
 
 cells by cell-mediated immune responses.
Many studies have demonstrated the role of CD4
 
1
 
 and
CD8
 
1
 
 T cells in the development of autoimmune type I
diabetes in NOD mice (1–12). However, the role of mac-
rophages in the pathogenesis of autoimmune diabetes in
these animals has not been well investigated. We and others
have shown that the major populations of cells infiltrating
the islets during the early stage of insulitis in BB rats and
NOD mice are macrophages and dendritic cells (13–17).
This infiltration precedes invasion of the islets by T lym-
phocytes, NK cells, and B lymphocytes (18). In addition,
electron microscopy has revealed that most of the single
cells present at an early stage of insulitis in BB rats are
macrophages (13). Intraperitoneal injections of silica, a
substance known to be toxic to macrophages, into cyclo-
phosphamide (CY)-treated NOD mice or BB rats almost
completely prevents the development of diabetes and insu-
litis (19–21). This result suggests that macrophages play an
important role in the development of insulitis and diabetes
in NOD mice. However, the mechanisms involved in the
prevention of 
 
b
 
 cell destruction by the inactivation of mac-
rophages in NOD mice remain unknown.
The purpose of this study is to determine the mecha-
nisms involved in the prevention of T cell–mediated au-
toimmune diabetes in macrophage-depleted NOD mice.
 
1
 
Abbreviations used in this paper:
 
 BB, BioBreeding; CY, cyclophosphamide;
FasL, Fas ligand; GAD, glutamic acid decarboxylase; HPRT, hypoxan-
thine phosphoribosyl transferase; lip-Cl
 
2
 
MDP, liposomal dichloromethy-
lene diphosphonate; NOD, nonobese diabetic. 
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We report that T cells in a macrophage-depleted environ-
ment lose their ability to differentiate into 
 
b
 
 cell–cytotoxic
T cells that can kill 
 
b
 
 cells. However, if these T cells are re-
turned to an environment containing macrophages and/or
the macrophage-derived cytokine IL-12 for a sufficient pe-
riod of time, they regain the ability to differentiate into 
 
b
 
cell–cytotoxic cells. We conclude that macrophages are
primary contributors to the creation of the immune envi-
ronment for the development and activation of 
 
b
 
 cell–spe-
cific Th1-type CD4
 
1
 
 T cells and CD8
 
1
 
 cytotoxic T cells
that cause autoimmune diabetes in NOD mice.
 
Materials and Methods
 
Animals.
 
NOD mice were originally obtained from Taconic
Farms; NOD.
 
scid
 
 mice were obtained from The Jackson Labora-
tory. The animals were bred and maintained under specific patho-
gen-free conditions and provided with sterile food and water
 
 
 
ad
libitum at the Animal Resource Centre, Faculty of Medicine, Uni-
versity of Calgary. Female NOD mice were used throughout the ex-
periments, with the exception of the male animals used for the prep-
aration of islets for transplantation. The use and care of the animals
used in this study were approved by the Animal Care Committee,
Faculty of Medicine, University of Calgary.
 
Preparation and Administration of Liposomal Dichloromethylene
Diphosphonate.
 
Phosphatidyl choline (86 mg; Lipoid GmbH,
Ludwigshafen, Germany) and cholesterol (8 mg; Sigma Chemical
Co., St. Louis, MO) were dissolved in chloroform as described
previously (22). This solution was evaporated by rotation in a
vacuum at 37
 
8
 
C and dispersed by mixing with 10 ml of PBS con-
taining 2.5 g of Cl
 
2
 
MDP (a gift from Boehringer Mannheim
GmBH). This mixture was sonicated for 3 min in a water bath
sonicator at room temperature and then set aside for 2 h at
room temperature. The resulting liposomes were centrifuged at
100,000 
 
g
 
 for 30 min to remove the nonencapsulated Cl
 
2
 
MDP.
The pellet was washed two to three times with PBS by centrifu-
gation at 25,000 
 
g
 
 for 30 min. The final liposomal dichlorometh-
ylene diphosphonate (lip-Cl
 
2
 
MDP) was suspended in 4 ml of
PBS before use (22, 23).
 
Treatment of NOD Mice with lip-Cl
 
2
 
MDP.
 
Female NOD mice
were treated with lip-Cl
 
2
 
MDP (200 
 
m
 
l/mouse) by intraperitoneal
administration once a week from 3 to 20 wk of age to deplete
macrophages. As a control group, NOD mice were treated with
PBS (200 
 
m
 
l/mouse). The incidence of diabetes was determined
by measurement of urine glucose using Diastix (Miles, Etobicoke,
ON, Canada) twice a week from 10 to 35 wk of age. Individual
mice were classified as diabetic on the basis of positive glycosuria
(
 
.
 
2) and hyperglycemia (blood glucose 
 
.
 
16.7 mM) as described
elsewhere (24–26).
 
Flow Cytometric Analysis.
 
Splenocytes were isolated from lip-
Cl
 
2
 
MDP– or PBS-treated NOD mice (2–3 mice/group) at 15
wk of age, as described previously (24). Splenocytes (1 
 
3
 
 10
 
6
 
cells) were incubated with Abs against B220, CD4, and CD8
(PharMingen) for 30 min at 4
 
8
 
C in staining buffer composed of
PBS containing 1% FCS and 0.1% sodium azide. After washing,
the cells were incubated with FITC-labeled secondary Ab (anti–
rat IgG) for 30 min at 4
 
8
 
C. For Mac1
 
1
 
 and CD11c
 
1
 
 cell staining,
FITC-labeled anti-Mac1 and PE-labeled anti-CD11c Ab were
used. The cells were then washed twice with staining buffer and
analyzed using a FACS
 
®
 
.
For analysis of Fas ligand (FasL) and perforin expression,
splenic T cells (10
 
6
 
 cells), purified using a T cell column (R&D
 
Systems) were stimulated with irradiated islets (40 islets) for 3 d in
complete RPMI 1640 medium, containing 10% FCS, 10 mM
Hepes buffer, 1 mM sodium pyruvate, 2 mM 
 
l
 
-glutamine, 100
U/penicillin, 0.1 mg/ml streptomycin, and 0.05 mM 
 
b
 
-mercap-
toethanol. Live cells were collected on a Ficoll gradient and
washed twice. For FasL staining, T cells were incubated with
biotinylated anti-FasL Abs (PharMingen) followed by incubation
with PE-conjugated streptavidin. For perforin staining, CD8
 
1 
 
T
cells were fixed with 4% paraformaldehyde, rendered permeable
using 1% saponin in PBS containing 1% FCS and 0.1% sodium
azide, and incubated with anti-perforin Abs (Kamiya Biomedical
Co.), followed by incubation with FITC-labeled anti–rat IgG.
 
In Vitro T Cell Proliferation Assay.
 
Single cell splenocytes were
prepared from 8–10-wk-old female NOD mice, and T cells were
purified using a T cell column (R&D Systems). The T cells (5 
 
3
 
10
 
5
 
 cells) were cultured with irradiated splenocytes (5 
 
3
 
 10
 
5
 
 cells)
from PBS- or lip-Cl
 
2
 
MDP–treated NOD mice, as APCs, in the
absence or presence of irradiated islets (4 
 
3
 
 10
 
4
 
 cells) or glutamic
acid carboxylase (GAD; 20 
 
m
 
g/ml) in 200 
 
m
 
l of complete RPMI
medium in a 96-well microplate for 96 h. The cells were pulsed
with [
 
3
 
H]thymidine (1 
 
m
 
Ci/well) for the last 16–18 h of the in-
cubation and then harvested. The incorporation of [
 
3
 
H]thymi-
dine was measured by liquid scintillation counting.
 
Adoptive Transfer of Splenocytes into NOD.scid Mice.
 
Splenocytes
were isolated from lip-Cl
 
2
 
MDP– and PBS-treated, nondiabetic
female NOD mice at 20 wk of age, as previously described (24).
The splenocytes from each donor were injected intravenously
(2 
 
3
 
 10
 
7
 
 cells/recipient) into 6–8-wk-old NOD.
 
scid
 
 mice. The
development of diabetes was determined by measurement of
urine and blood glucose from day 3 to day 90 after the transfer of
splenocytes, as described above. As a positive control, splenocytes
from acutely diabetic mice were injected into age-matched
NOD.
 
scid
 
 mice. For long-term observations, recipient mice were
kept up to 20 wk after the transfer of splenocytes and the inci-
dence of diabetes was determined by the measurement of urine
and blood glucose.
To determine whether long-term treatment with lip-Cl
 
2
 
MDP
affects established 
 
b
 
 cell–cytotoxic T cells, 16-wk-old female
nondiabetic NOD mice were treated intraperitoneally with lip-
Cl
 
2
 
MDP (200 
 
m
 
l/mouse per week) or PBS, as a control, once a
week up to wk 25 of age, and splenic T cells from nondiabetic
NOD mice were isolated and purified using a T cell column
(R&D Systems) 1 d after the last treatment (
 
z
 
65% of the lip-
Cl
 
2
 
MDP–treated NOD mice had become diabetic by the age of
25 wk). T cells were injected intravenously (10
 
7
 
 cells/mouse)
into 6–8-wk-old NOD.
 
scid
 
 mice. In a parallel experiment, female
NOD mice were treated with PBS or lip-Cl
 
2
 
MDP weekly from
19 to 21 wk of age. Splenic T cells (10
 
7
 
 cells/mouse) were trans-
fused into NOD.
 
scid
 
 mice as described above. The development
of diabetes was monitored by 10 wk after the transfer of T cells as
described above, and the incidence of diabetes was compared be-
tween the two experimental groups.
 
Transplantation of NOD Mouse Islets into lip-Cl
 
2
 
MDP–treated
NOD Mice.
 
Intact pancreatic islets were isolated from 4-wk-old
male NOD mice as previously described (27). To determine
whether cytotoxic T cells that can destroy 
 
b
 
 cells are generated in
the lip-Cl
 
2
 
MDP–treated NOD mice, 400 syngeneic islets were
transplanted under the renal capsule of each lip-Cl
 
2
 
MDP– and
PBS-treated control animal (5 mice/group) at 20 wk of age, as
previously described (27). The recipient mice were killed 3 wk
after transplantation, and serial sections of the kidney bearing the
transplanted islets were examined after hematoxylin and eosin
staining (27) to check for lymphocytic infiltration. 
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Reverse Transcriptase PCR Analysis of Cytokine Gene Expression.
 
Total RNA was extracted from the total splenocytes or puri-
fied splenic T cells of lip-Cl
 
2
 
MDP– and PBS-treated NOD
mice with a T cell column (R&D Systems) using Trizol (GIBCO
BRL) according to the manufacturer’s protocol. For analysis of
mRNA of FasL and perforin, purified T cells were activated with
irradiated NOD islets for 72 h before the extraction of RNA. 3
 
m
 
g of total RNA was used to synthesize cDNA using Superscript
II reverse transcriptase (GIBCO BRL) and oligo(dT)
 
12–18
 
.
 
 
 
PCR
was performed using specific primers for various cytokine genes,
as previously described (28). The upstream and downstream
primers used were as follows: IL-2: sense, CTTGCCCAAGCA-
GGCCACAG, antisense, GAGCCTTATGTGTTGTAAGC;
IFN-
 
g
 
: sense, AGCTCTGAGACAATGAACGC, antisense, GGA-
CAATCTCTTCCCCACCC; IL-4: sense, TCTTTCTCGAATG-
TACCAGG, antisense, CATGGTGGCTCAGTACTACG; IL-10:
sense, CAAACAAAGGACCAGCTGGAC, antisense, GAGTCC-
AGCAGACTCAATAC; TNF-
 
a
 
: sense, CCTGTAGCCCACG-
TCGTAGC, antisense, TTGACCTCAGCGCTGAGTTG; IL-1
 
b
 
:
sense, GAATGACCTGTTCTTTGAAGTT, antisense, TTTT-
GTTGTTCATCTCGGAGCC; IL-12: sense, AGAGGTGGACT-
GGACTCCCGA, antisense, TTTGGTGCTTCACACTTCAGC;
IL-12R
 
b
 
1: sense, GTACTCCACGACACGTGTCGG, antisense,
GTCCGCTCGCACCTGAACCTT; IL-12R
 
b
 
2: sense, AGTG-
GACCAAACAATCTGAC, antisense, ATCTTCCCACTGCAG-
TGTAC; perforin: sense, AACTTCCTAATGAGAGACGCC,
antisense, AAGTCAAGGTGGAGTGGAGG; FasL: sense, CAG-
CTCTTCCACCTGCAG, antisense, TTAAAGCTTATACAA-
GCC. Hypoxanthine phosphoribosyl transferase (HPRT) was used
as an internal standard. The primers used for HPRT were: sense,
GTAATGATCAGTCAACGGGGGAC, antisense, CCAGCAA-
GCTTGCAACCTTAACCA. The PCR condition was opti-
mized for each set of primers. PCR was performed using differ-
ent numbers of cycles to ensure that amplification occurred in a
linear range. The PCR mixture (50 
 
m
 
l) contained 0.2 mM of
each deoxynucleotide triphosphate, 1 
 
m
 
M of each specific
primer, 1.5 mM or 2 mM MgCl
 
2
 
, 50 mM KCl, 10 mM Tris-Cl,
pH 9.0, and 2.5 U of Taq polymerase (Pharmacia Biotech). After
amplification, the products were subjected to electrophoresis on a
1.5% agarose gel and detected by ethidium bromide staining.
 
Quantitative ELISA of Cytokine Production.
 
Splenic T cells (10
 
6
 
cells) were prepared from 15-wk-old lip-Cl
 
2
 
MDP– or PBS-
treated mice (3 mice/group). The cells were washed with serum-
free RPMI 1640 medium and incubated for 48 h in anti-CD3 Ab
(10 
 
m
 
g/ml)-coated wells or for 72 h with irradiated NOD islets
in complete RPMI 1640 medium. The supernatant was collected
and cytokine release was measured using a Quantikine ELISA kit
(R&D Systems) according to the manufacturer’s protocol (28).
 
Administration of rIL-12.
 
Recombinant mouse IL-12 (R&D
Systems) (0.4 
 
m
 
g/200 
 
m
 
l of PBS, containing 1% syngeneic NOD
mouse serum, per mouse for 1 wk followed by 0.2 
 
m
 
g/200 
 
m
 
l of
PBS per mouse for 3 wk) was administered intraperitoneally each
day commencing at 9 wk of age, to NOD mice which had been
treated with lip-Cl
 
2
 
MDP or PBS from 3 wk of age. Control
groups of lip-Cl
 
2
 
MDP or PBS treated NOD mice received 200 
 
m
 
l
of PBS, containing 1% syngeneic mouse serum, in place of IL-12
each day. The development of diabetes was monitored by mea-
suring glycosuria (
 
.
 
2) every second day (24) and confirmed by
the measurement of blood glucose (
 
.16.7 mM) (25, 26).
Histology. The pancreata were removed from lip-Cl2MDP–
and PBS-treated NOD mice killed at 25 wk of age. Pieces of each
pancreas were fixed with 10% buffered formalin, embedded in par-
affin, sectioned at 4.5 mM, and stained with hematoxylin and eosin.
Statistical Analysis. The statistical significance of differences
between groups was analyzed by Student’s t test. A level of P ,
0.05 was accepted as significant. Data are expressed as means 6 SD.
Results
Macrophages Are Required for the Development of b Cell–
cytotoxic T Cells in NOD Mice. Previously, we found that
the depletion of macrophages by treatment with silica pre-
vents the development of diabetes in CY-treated NOD
mice (19). First, to confirm that the depletion of macro-
phages prevents the development of diabetes and to deter-
mine whether lip-Cl2MDP has the same effect as silica on
the prevention of diabetes in NOD mice, we treated NOD
mice from 3 to 20 wk of age with lip-Cl2MDP, which spe-
cifically depletes macrophages (22, 29, 30). We then exam-
ined the cumulative incidence of diabetes by 35 wk of age.
We found that none of the lip-Cl2MDP–treated NOD
mice developed diabetes. In contrast, 80% (8 out of 10) of
Figure 1. Depletion of macrophages in NOD mice by treatment with
lip-Cl2MDP results in the prevention of diabetes. 12 3-wk-old female
NOD mice were treated weekly with 200 ml of lip-Cl2MDP (d) until 20 wk
of age; 10 female NOD mice were treated similarly with PBS (s). The
cumulative incidence of diabetes was measured.
Table I. Depletion of Macrophages Results in the Prevention of 
Insulitis in NOD Mice
Treatment*
Insulitis grade‡
0 1 234
%
P B S 391 13 54 2
lip-Cl2MDP 91 5 3 1 0
*200 ml of lip-Cl2MDP per mouse was injected intraperitoneally into
female NOD mice weekly from 3 to 20 wk of age.
‡At 25 wk of age, five randomly selected nondiabetic mice were killed
and at least 20 islets per mouse were examined. Grade: 0, normal islets;
1, mononuclear infiltration, largely in the periphery, in ,25% of the is-
lets; 2, 25–50% of islets infiltrated; 3, .50% of islets infiltrated; 4, small,
retracted islets with few mononuclear cells.350 Role of Macrophages in the Pathogenesis of Autoimmune Type I Diabetes
the PBS-treated control NOD mice developed diabetes by
the same age (Fig. 1). We also examined the development
of insulitis in the lip-Cl2MDP– and PBS-treated NOD
mice at 25 wk of age. 91% of the examined islets from the
lip-Cl2MDP–treated mice were intact (Table I, Fig. 2 A).
In contrast, 88% of the examined islets from the PBS-
treated control mice showed moderate to severe insulitis
(Table I, Fig. 2 B). These results indicate that macrophages
are an absolute requirement for the development of au-
toimmune diabetes in NOD mice.
It is known that the development of autoimmune dia-
betes in NOD mice is T cell mediated. To determine
whether macrophages are required for the development of
b cell–cytotoxic T cells, we transfused splenocytes from ei-
ther lip-Cl2MDP– or PBS-treated control NOD mice into
6–8-wk-old NOD.scid mice. None (0 out of 6) of the re-
cipients of lip-Cl2MDP–treated NOD splenocytes devel-
oped diabetes, whereas 83% (5 out of 6) of the recipients of
splenocytes from PBS-treated control NOD mice became
diabetic within 8 wk of transfusion. Similarly, 100% (7 out
of 7) of the recipients of splenocytes from newly diabetic
NOD mice became diabetic by 9 wk after transfer of the
splenocytes (Fig. 3).
To determine whether T lymphocytes in lip-Cl2MDP–
treated NOD mice can destroy pancreatic b cells, we trans-
planted intact, syngeneic NOD mouse pancreatic islets into
the renal capsule of lip-Cl2MDP–treated NOD mice (20 wk
of age). A majority of the grafted islets remained intact .3 wk
after transplantation (Table II, Fig. 4 A). In contrast, most
of the syngeneic islets transplanted into age-matched, PBS-
treated NOD mice were destroyed within 3 wk of trans-
plantation (Table II, Fig. 4 B). These results indicate that
macrophages are required for the development of cytotoxic
T cells that can cause b cell destruction in NOD mice.
Figure 2. Photomicrographs of the pancreatic islets of NOD mice.
Pancreatic sections from 25-wk-old female NOD mice treated with lip-
Cl2MDP (A) or PBS (B) were stained with hematoxylin and eosin. Islets
from the lip-Cl2MDP–treated mice are intact (A). In contrast, islets from
the PBS-treated animals show severe insulitis (B). Original magnification:
3250.
Figure 3. Depletion of macrophages in NOD mice results in the failure
of adoptive transfer of diabetes to NOD.scid mice by splenocytes.
NOD.scid mice (6–8-wk-old) received splenocytes (2 3 107 cells) isolated
from 20-wk-old lip-Cl2MDP–treated (n 5 6, d) or PBS-treated (n 5 6,
s) NOD mice or from newly diabetic (n 5 7, m) NOD mice.
Table II. Prevention of Insulitis in Islets Grafted into 
lip-Cl2MDP–treated NOD Mice
Islet recipient* Insulitis grade in islet grafts‡
Strain Treatment 01234
%
NOD PBS 0 2 12 38 48
lip-Cl2MDP 85 11 3 1 0
*Pancreatic islets were prepared from 4-wk-old male NOD mice and
transplanted under the renal capsule of NOD mice at 20 wk of age that
had been treated with lip-Cl2MDP from 3 to 20 wk of age (5 mice/
group). Insulitis was examined 3 wk after transplantation.
‡Insulitis in the islet grafts was graded as in Table I.351 Jun et al.
Splenic T Cells from Macrophage-depleted NOD Mice Are
Able to Recover Their Ability to Differentiate into b Cell–cyto-
toxic T Cells in the Presence of Macrophages. To determine
whether splenic T cells from macrophage-depleted NOD
mice are able to recover their ability to differentiate into b
cell–cytotoxic T cells in the presence of macrophages, we
transfused splenocytes isolated from macrophage-depleted
NOD mice into NOD.scid mice and made observations for
a prolonged period of time (13–20 wk). None of the recip-
ients developed diabetes earlier than 13 wk after splenocyte
transfer; however 71% (5 out of 7) developed diabetes be-
tween 14 and 17 wk after the transfusion (Fig. 5). In con-
trast, 86% (6 out of 7) of the recipients of splenocytes from
PBS-treated NOD mice became diabetic within 8 wk of
transfusion and 100% (5 out of 5) of the recipients of sple-
nocytes from newly diabetic NOD mice became diabetic
within 7 wk of the transfusion (Fig. 5). This suggests that
prolonged exposure to the endogenous macrophages in
NOD.scid mice can provide the necessary immune envi-
ronment required to differentiate the splenic T cells from
macrophage-depleted mice into b cell–cytotoxic T cells.
Long-Term Treatment with lip-Cl2MDP Does Not Alter the
Function of Established b Cell–cytotoxic T Cells in NOD
Mice. To determine whether treatment with lip-Cl2MDP
alters the function of established b cell–cytotoxic T cells in
NOD mice, we treated NOD mice with lip-Cl2MDP or
PBS, as a control, weekly for a short period (3 wk) and a
longer period (9 wk) at the age of z20 wk (19–21 and
16–25 wk of age, respectively). These particular age ranges
were chosen because b cell–cytotoxic T cells have devel-
oped in NOD mice by around these ages. We isolated
splenic T cells from short-term or long-term PBS- or lip-
Cl2MDP–treated NOD mice, transfused them into 6–8-wk-
old NOD.scid mice, and examined the incidence of diabe-
tes in the NOD.scid mice. We found no difference in the
incidence of diabetes between the NOD.scid recipients of
T cells from PBS-treated NOD mice and the recipients of
T cells from lip-Cl2MDP–treated NOD mice (Table III).
In addition, no statistically significant difference was found
in the incidence of diabetes between NOD.scid recipients
of T cells from short-term lip-Cl2MDP–treated (3 wk) and
long-term lip-Cl2MDP–treated (9 wk) NOD mice. This
Figure 4. Histology of islet
grafts in the renal capsule of lip-
Cl2MDP– and PBS-treated NOD
recipients. Syngeneic islets were
transplanted under the renal cap-
sule of  lip-Cl2MDP– and PBS-
treated NOD mice at 20 wk of
age and the animals were killed
3 wk later. Sections of the kidney
bearing the islet grafts were stained
with hematoxylin and eosin. (A)
Section from lip-Cl2MDP–treated
NOD mouse recipient shows in-
tact islet graft (single arrow). (B)
Section from PBS-treated mouse
recipient shows necrosis and mas-
sive infiltration by lymphocytes
(double arrows). Original magnifi-
cation: 3200.352 Role of Macrophages in the Pathogenesis of Autoimmune Type I Diabetes
IFN-g mRNA was decreased in splenic T cells from lip-
Cl2MDP–treated NOD mice as compared with that in
PBS-treated control NOD mice. In contrast, the expres-
sion of both IL-4 and IL-10 mRNA was increased in the
splenic T cells from lip-Cl2MDP–treated NOD mice as
compared with the expression in PBS-treated controls (Fig.
6 A).
To ascertain the islet antigen-specific cytokine secretion,
we activated splenic T cells isolated from lip-Cl2MDP– or
PBS-treated NOD mice using anti-CD3 Ab or NOD
mouse pancreatic islets, and measured the IFN-g and IL-4
cytokine secretion. A low level of IFN-g secretion, but a
high level of IL-4 secretion, was found in lip-Cl2MDP–
treated NOD mice as compared with the levels in PBS-
treated control NOD mice when the splenic T cells were
activated with anti-CD3 Ab (Fig. 6 C) or NOD mouse
pancreatic islets (Fig. 6 D). These results indicate that the
inactivation of macrophages in NOD mice results in a de-
crease in the Th1 immune response along with an increase
in a Th2-type immune response after both antigen-specific
and nonspecific stimulation.
It has been found that the IL-12Rb2 subunit, but not
the IL-12Rb1 subunit, is preferentially expressed in Th1-
type CD41 T cells (31). To determine whether there is any
change in the expression of the IL-12Rb2 subunit in
splenic T cells from lip-Cl2MDP–treated NOD mice, we
examined the expression of the IL-12R in splenic T cells
from these mice and PBS-treated control NOD mice. The
expression of the IL-12Rb2 subunit was significantly de-
creased in lip-Cl2MDP–treated NOD mice as compared
with that in the PBS-treated control animals (Fig. 6 B).
This result supports the finding that the depletion of mac-
rophages results in a decrease in the Th1 immune response
in NOD mice.
Depletion of Macrophages Does Not Alter the Lymphocyte
Subset Population. To determine whether there is any
change in the number of immunocytes in the spleens from
lip-Cl2MDP–treated NOD mice, FACS® analysis of im-
munocytes was carried out. Mac11 cells were clearly de-
creased in lip-Cl2MDP–treated NOD mice. There was no
significant difference in the number of B220-positive B
cells or CD41 T cells between lip-Cl2MDP– and PBS-
treated NOD mice. The number of CD81 T cells appears
to have declined in the lip-Cl2MDP–treated NOD mice as
compared with the PBS-treated control mice (15% in PBS-
treated control mice versus 11% in lip-Cl2MDP–treated
mice). However, there was no statistically significant differ-
ence (P . 0.05) between the macrophage-depleted and
control animals (Table IV). Similarly, CD11c1 cells, a
marker for dendritic cells, appear to have declined in lip-
Cl2MDP–treated NOD mice (2.7%) as compared with
PBS-treated control mice (3.6%). However, there was no
statistically significant difference (P 5 0.067) between the
lip-Cl2MDP– and PBS-treated groups (Table IV).
Treatment of NOD Mice with lip-Cl2MDP Results in a De-
crease in the Gene Expression of the Macrophage-derived Cyto-
kines. To determine whether a shift in the immune
response of macrophage-depleted mice, specifically a de-
result indicates that neither short- nor long-term treatment
with lip-Cl2MDP alters the function of established b cell–
cytotoxic T cells in NOD mice, since these T cells are able
to induce diabetes.
Depletion of Macrophages Results in a Decrease in the Th1
Immune Response and an Increase in the Th2 Immune Response
in NOD Mice. As Th1 development may be mediated by
macrophage-derived cytokines, particularly IL-12, we de-
termined whether the depletion of macrophages would re-
sult in a change in the Th1 and Th2 immune responses by
examining the expression of cytokine mRNAs (IL-2 and
IFN-g for the Th1 response and IL-4 and IL-10 for the
Th2 response) in the splenic T cells from lip-Cl2MDP– or
PBS-treated NOD mice. The expression of both IL-2 and
Figure 5. Splenic T cells from lip-Cl2MDP–treated mice can recover the
capability to differentiate into cytotoxic effector T cells in the presence of
macrophages. NOD.scid mice (7 wk old) received splenocytes (2 3 107 cells)
isolated from 20-wk-old lip-Cl2MDP–treated (n 5 7, d) or PBS-treated
(n 5 7, s) NOD mice or from newly diabetic NOD mice (n 5 5, n).
Table III. Long-Term Treatment with lip-Cl2MDP Does Not 
Alter the Function of Established b Cell–cytotoxic T Cells in
NOD Mice
Treatment of donors
(NOD mice)
Incidence of diabetes in recipients
(NOD.scid mice)* Treatment Duration
wk
PBS 3 80% (4/5)
9 83% (5/6)
lip-Cl2MDP 3 75% (3/4)
9 86% (6/7)
Female NOD mice were treated with PBS or lip-Cl2MDP once a
week from 19 to 21 wk of age (3-wk duration of treatment) or from 16
to 25 wk (9-wk duration of treatment). Splenic T cells (107 T cells/
mouse) were transfused intravenously into 6–8-wk-old NOD.scid
mice.
*Cumulative incidence of diabetes by 10 wk after transfer of T cells.
Parentheses indicate number of animals which developed diabetes over
total number of animals tested.353 Jun et al.
crease in the Th1 immune response and an increase in the
Th2 immune response, is due to changes in the macro-
phage-derived cytokine IL-12, we examined the expression
of IL-12 in splenic macrophages from lip-Cl2MDP– and
PBS-treated NOD mice using reverse transcriptase PCR
analysis. We found that the gene expression of IL-12 was
significantly decreased in the lip-Cl2MDP–treated NOD
mice as compared with that in the PBS-treated controls
(Fig. 7). In addition, the expression of other macrophage-
derived cytokines, IL-1b and TNF-a, also were decreased
in the lip-Cl2MDP–treated NOD mice (Fig. 7). This result
suggests that a shift from a Th1 immune response to Th2
immune response may be due to the decreased expression
of macrophage-derived cytokines, particularly IL-12.
Administration of IL-12 Substantially Reverses the Preventive
Effect of lip-Cl2MDP in NOD Mice. The treatment of NOD
mice with lip-Cl2MDP results in a significant decrease in
the expression of the macrophage-derived cytokine IL-12
and in the decrease of Th1-type immune responses. To de-
termine whether IL-12, which is known to play an impor-
tant role in the induction of Th1-type immune responses,
reverses the preventive effect of lip-Cl2MDP in NOD
mice, we treated NOD mice with lip-Cl2MDP with or
without IL-12. 43% (3 out of 7) of the IL-12 co-injected
NOD mice developed diabetes, whereas none (0 out of 9)
of the mice treated with lip-Cl2MDP alone developed the
disease (Fig. 8). In contrast, 83% (5 out of 6) of the age-
matched PBS-treated control mice (no lip-Cl2MDP treat-
ment) that were injected with IL-12 developed diabetes by
8 wk after IL-12 injection (17 wk of age at the time of on-
set of diabetes). 60% (6 out of 10) of the mice that were
treated with PBS alone developed diabetes by 22 wk of age
(Fig. 8). These results indicate that IL-12 substantially re-
Figure 6. Depletion of mac-
rophages results in a decrease in
the Th1 immune response and
an increase in the Th2 immune
response in NOD mice. Splenic
T cells were isolated from three
mice (15 wk of age) from each
group. Reverse transcriptase
PCR analysis for cytokine gene
expression was performed using
primers specific for IL-2, IFN-g,
IL-4, and IL-10 (A) and IL-
12Rb1 and IL-12Rb2 (B).
Primers for HPRT were used as
standards. M, 100-bp ladder; 1,
amplified product from splenic T
cells of PBS-treated NOD mice;
2, amplified product from
splenic T cells of lip-Cl2MDP–
treated NOD mice. Representa-
tive data for three independent
experiments are shown. For the
measurement of cytokine secre-
tion from splenic T cell cultures, splenic T cells were isolated from lip-Cl2MDP– and PBS-treated NOD mice (n 5 3 per group, 15 wk of age), and ac-
tivated with anti-CD3 Ab (10 mg/ml) for 2 d (C) or with irradiated NOD islets for 3 d (D). The production of cytokine levels was determined by
ELISA. Values are shown as mean 6 SD of three independent experiments. *P , 0.05 compared with PBS-treated control group.
Figure 7. Treatment of NOD mice with lip-
Cl2MDP results in a decrease in the gene ex-
pression of macrophage-derived cytokines.
Splenocytes were pooled from three mice (15
wk of age) in each group. RNA was extracted
from the splenocytes and reverse transcriptase
PCR analysis for cytokine gene expression was
performed using primers specific for IL-1b,
TNF-a, and IL-12. M, 100-bp ladder; 1, am-
plified product from splenocytes of PBS-treated
NOD mice; 2, amplified product from spleno-
cytes of lip-Cl2MDP–treated NOD mice. Rep-
resentative data from three independent experi-
ments are shown.
Table IV. Treatment with lip-Cl2MDP Does Not Alter T and B 
Lymphocyte Populations in NOD Mice
Antibody
against*
Treatment
PBS‡ lip-Cl2MDP‡
%
Mac1 8.3 6 1.2 1.9 6 0.3§
CD4 35.4 6 7.0 31.1 6 4.6
CD8 14.5 6 2.6 11.4 6 2.2i
B220 36.7 6 4.0 38.2 6 5.2
CD11c 3.6 6 0.4 2.7 6 0.3i
*Splenocytes were isolated from PBS- and lip-Cl2MDP–treated NOD
mice at 15 wk of age, stained with the designated antibody, and ana-
lyzed by FACScan®.
‡Data shown represent mean 6 SD from three different experiments.
§P , 0.05 compared with PBS-treated control mice.
iP . 0.05 compared with PBS-treated control mice.354 Role of Macrophages in the Pathogenesis of Autoimmune Type I Diabetes
verses the preventive effect of lip-Cl2MDP in NOD mice,
probably due to the induction of Th1-type immune re-
sponses.
The Function of Antigen Presentation Is Reduced in Macro-
phage-depleted NOD Mice. One role of macrophages is the
processing and presentation of antigens to CD41 helper T
cells in association with MHC class II molecules. If these
antigen-processing and presenting functions are decreased,
then CD41 T cell activation also would be reduced. Thus,
we determined the T cell proliferative response to islet
antigens and GAD, a well known b cell autoantigen, in
the presence of irradiated splenocytes from either lip-
Cl2MDP– or PBS-treated NOD mice. The T cell prolifer-
ative response against islets and GAD was significantly de-
creased in the presence of lip-Cl2MDP–treated splenocytes,
as compared with the response in the presence of PBS-
treated splenocytes (Fig. 9). These results indicate that the
function of antigen presentation in macrophage-depleted
NOD mice is significantly impaired.
Inactivation of Macrophages Results in a Decrease in the Ex-
pression of FasL and Perforin. FasL and perforin are known
to show increased expression in activated T cells (32). To
determine whether there is any change in the expression
level of FasL and perforin in the splenic T cells in mac-
rophage-depleted NOD mice, we measured the mRNA
expression of FasL and perforin in splenic T cells from lip-
Cl2MDP–treated NOD mice after stimulation with NOD
islets. We found a significant decrease in expression as
compared with that in PBS-treated control NOD mice
(Fig. 10 A). To confirm this result at the protein level, we
analyzed the expression of FasL and perforin after activa-
tion with syngeneic NOD islets, using flow cytometry. We
found that the expression of FasL and perforin in T cells
were also significantly downregulated in lip-Cl2MDP–
treated NOD mice as compared with PBS-treated control
NOD mice (Fig. 10, B and C).
Figure 8. Administration of IL-12 substantially reverses the preventive
effect of lip-Cl2MDP in NOD mice. Female NOD mice were treated
with lip-Cl2MDP once a week from 3 wk of age. Recombinant mouse
IL-12 (0.4 mg/200  ml PBS/mouse) was administered intraperitoneally
each day for the first week beginning at 9 wk of age; and then 0.2 mg of
IL-12 was injected daily for the next 3 wk (s). As a control, IL-12 was
administered as described above to NOD mice that had not received lip-
Cl2MDP treatment (n). As an additional control, to determine the inci-
dence of spontaneously developed diabetes in NOD mice, NOD female
mice received PBS (200 ml/mouse) daily (m). To determine the effect of
lip-Cl2MDP treatment on the prevention of diabetes, NOD female mice
were treated with lip-Cl2MDP only (d). The incidence of diabetes was
assessed by the measurement of urine glucose every other day.
Figure 9. The antigen-presenting function is significantly decreased in
macrophage-depleted NOD mice. Splenic T cells (5 3 105 cells) from 8–10-
wk-old female NOD mice (n 5 4) were cultured with irradiated spleno-
cytes (5 3 105 cells) from PBS- or lip-Cl2MDP–treated NOD mice in the
presence or absence of the antigens indicated, in 200 ml of complete
RPMI 1640 medium. [3H]thymidine incorporation was measured. The
bar represents SD value from 4 different mice. *P , 0.05 compared with
PBS-treated controls.
Figure 10. Inactivation of macrophages results in a decrease in the ex-
pression of FasL and perforin. In each group, splenic T cells were pooled
from three mice (15 wk of age) and activated with irradiated NOD islets
for 72 h. Reverse transcriptase PCR was performed using primers specific
for FasL and perforin (A). Primers for HPRT were used as standards. M,
100-bp ladder; 1, amplified product from splenic T cells of PBS-treated
NOD mice; 2, amplified product from splenic T cells of lip-Cl2MDP–
treated NOD mice. Representative data from three independent experi-
ments. For FACS® analysis of FasL (B) and perforin (C) expression,
splenic T cells (106 cells) were stimulated with irradiated islets (40 islets)
for 3 d and stained with biotinylated anti-FasL or anti-perforin Abs fol-
lowed by incubation with PE-streptavidin and FITC-labeled anti–rat
IgG, respectively. Solid-line histograms represent cells incubated with
PE-streptavidin or FITC-labeled anti–rat IgG only. Dashed line histo-
grams represent cells stained with anti-FasL or anti-perforin Abs. Upper
panel shows the results for PBS-treated control mice; lower panel shows
the results for lip-Cl2MDP–treated mice.355 Jun et al.
Discussion
Type I diabetes is a T cell–mediated autoimmune disease
found both in humans and in animal models. The role of T
cells in the pathogenesis of autoimmune type I diabetes in
NOD mice has been studied extensively (1–12). Activated
Th1-type CD41 and CD81 T cells are believed to kill b
cells by apoptosis induced by TNF-a–TNF-a receptor in-
teractions (33) and Fas–FasL and/or perforin–granzyme
pathways (1, 3). However, the mechanisms by which these
cytotoxic T cells develop are not well understood. The de-
pletion of macrophages results in the complete prevention
of T cell–mediated autoimmune type I diabetes in CY-
treated NOD mice (19). Thus, it has been suggested that
macrophages play an important role in the pathogenesis of
autoimmune type I diabetes (3). However, the role of mac-
rophages in the T cell–mediated autoimmune process has
not been elucidated.
The first question posed in this study was whether mac-
rophages are required for the development of cytotoxic T
cells that can destroy b cells. We transfused splenocytes
from macrophage-depleted NOD mice into NOD.scid
mice, and found that none of the recipients developed dia-
betes, whereas the majority of the NOD.scid recipients of
splenocytes from age-matched, PBS-treated control NOD
mice became diabetic within 8 wk of transfer. These results
clearly indicate that macrophages are an absolute require-
ment for the development of b cell–cytotoxic T cells in
NOD mice. Next, to determine whether T lymphocytes
from macrophage-depleted NOD mice can destroy pan-
creatic b cells, we transplanted insulitis-free islets into the
renal capsule of macrophage-depleted NOD mice at 20 wk
of age. The T cells in the macrophage-depleted NOD mice
recipients did not destroy the transplanted islets, whereas
the T cells in age-matched control NOD mice recipients
destroyed the transplanted islet cells within 3 wk after
transplantation. These results confirm that T cells in a mac-
rophage-depleted environment lose their ability to differ-
entiate into cytotoxic T cells that can destroy pancreatic b
cells.
The second question posed in this study was whether
long-term treatment of NOD mice with lip-Cl2MDP af-
fects the established b cell–cytotoxic T cells, resulting in a
loss of their ability to destroy b cells. To answer this ques-
tion, we treated NOD mice with lip-Cl2MDP for a pro-
longed period (9 wk) after the development of b cell–cyto-
toxic T cells in these animals, and transfused T cells from
these mice into NOD.scid mice. We found that the trans-
fused T cells were able to induce diabetes as did the T cells
from PBS-treated control NOD mice. This result indicates
that long-term treatment with lip-Cl2MDP does not alter
the function of the established b cell–cytotoxic T cells in
NOD mice.
Several reports have shown that lip-Cl2MDP selectively
depletes macrophages without affecting nonphagocytic cells
(22, 29, 30, 34–39). The large liposomes (.0.8 mm) used
in this study are selectively phagocytosed by macrophages,
whereas small liposomes (,0.2 mm) may be internalized by
nonphagocytic cells. In fact, macrophages phagocytose lip-
Cl2MDP, and the phospholipid bilayers of the liposomes
are disrupted by lysosomal phospholipase. Cl2MDP is then
released intracellularly, and kills macrophages by apoptosis.
Therefore, only cell populations that possess both phago-
cytic activity and phospholipase can be affected. Thus, we
cannot exclude the possibility that lip-Cl2MDP treatment
may have some effect on a certain dendritic cell population,
which possesses both a phagocytic function and lysosomal
phospholipase. However, CD41 and CD81 T and B cells,
which have neither a phagocytic function nor lysosomal
phospholipase, are not affected by treatment with lip-
Cl2MDP. It had been thought that free Cl2MDP released
from dying macrophages may be toxic to other immune
cells. However, free Cl2MDP is rapidly excreted by the
kidneys (,10 min) (van Rooijen, N., unpublished obser-
vation). Furthermore, lip-Cl2MDP has a very short half-life
in circulation and within body fluids, explaining why it
does not affect nonphagocytic cells (35). Finally, the spe-
cific depletion of macrophages by lip-Cl2MDP treatment
has been confirmed by immunocytochemical and electron
microscopic methods and by functional assays (36, 37).
The third question posed in this study was whether T
cells from macrophage-depleted NOD mice would recover
their ability to differentiate into cytotoxic T cells when
transferred into a macrophage-containing environment. To
answer this question, we transfused splenocytes from mac-
rophage-depleted NOD mice into NOD.scid mice (which
contain endogenous macrophages but lack T cells) and
monitored urine glucose for a prolonged time period. In
agreement with the previous experiment, none of the mice
became diabetic up to 13 wk after transfusion, but z70%
became diabetic between 14 and 17 wk after the transfer of
splenocytes. This supports our findings that macrophages
are a major contributor to the creation of the immune en-
vironment required for the development of b cell–cyto-
toxic T cells.
The fourth question posed in this study was why T cells
from a macrophage-depleted environment lose their ability
to destroy b cells. One possible cause for the impaired ca-
pability of T cells to kill b cells in macrophage-depleted
NOD mice is a change in the finely tuned balance of
immunoregulatory T cells, involving a decrease in the Th1
immune response along with an increase in the Th2 im-
mune response. As macrophage-derived IL-12 is a domi-
nant factor in directing the development of Th1 cells, the
depletion of macrophages would be expected to impair the
production of IL-12 and suppress the Th1 immune re-
sponse. It has been suggested that Th1-type T cells play a
pathogenic role in the autoimmune destruction of b cells in
autoimmune diabetes (12, 40–42), whereas Th2-type T
cells play a nondestructive or preventive role in the disease
(12, 42–44). Thus, it is thought that the destruction of b
cells may depend on which way the finely tuned balance of
immunoregulatory T cells (i.e., Th1- and Th2-type T cells)
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secreted from Th1-type T cells or IL-4 secreted from Th2-
type T cells) is tipped. If this balance is tipped in favor of
Th1-type effector T cells and/or their immune-activating
cytokines, the autoimmune process leading to b cell
destruction may be enhanced. In contrast, Th2-type T cells
and/or their immunosuppressive cytokines may protect the
b cells against immune-activating effector T cell–mediated
damage when the immune balance is tipped in their favor,
blocking the autoimmune destructive process. We found
that the level of IL-4 secreted from Th2-type T cells in-
creased, whereas IFN-g secreted from Th1-type T cells de-
creased in macrophage-depleted NOD mice.
In addition, a recent study shows that the IL-12Rb2 sub-
unit is preferentially expressed in Th1-type T cells, whereas
the IL-12Rb1 subunit is expressed in both Th1- and Th2-
type T cells (31). Therefore, we examined the expression of
IL-12Rb2 in the splenic T cells to confirm our finding of a
decrease in the Th1 immune response in T cells from mac-
rophage-depleted NOD mice. We found that the expres-
sion of IL-12Rb2 was significantly decreased in these T
cells, as compared with the expression in the T cells of con-
trol NOD mice that were not depleted of macrophages.
Thus, the decrease in the Th1 immune response along with
an increase in the Th2 immune response in macrophage-
depleted mice may be one major factor contributing to the
impairment of the capability of T cells to kill b cells.
The IL-12 expressed in macrophages is known to play an
important role in the development of Th1-type CD41 T
cells, leading to a T cell–mediated immune response (45,
46). Therefore, we examined whether the decrease of the
Th1 immune response is due to the decrease of IL-12 ex-
pression in lip-Cl2MDP–treated NOD mice. We found
that the expression of IL-12 in macrophage-depleted NOD
mice was significantly decreased as compared with age-
matched, control NOD mice. The fifth question posed in
this study was whether the administration of IL-12 would
negate the protective effect of macrophage depletion in
NOD mice. We found that the administration of IL-12
substantially, but not completely, reversed the prevention
of diabetes in macrophage-depleted NOD mice. These re-
sults suggest that the downregulation of IL-12 indirectly
protects b cells from destruction in macrophage-depleted
NOD mice by changing the finely tuned balance of the
Th1/Th2 immune response.
We also considered other factors that might protect b
cells from destruction in macrophage-depleted mice. These
include macrophage-derived soluble mediators such as ox-
ygen free radicals and other cytokines including IL-1b,
TNF-a, and IFN-g. We found that the expression of the
cytokines IL-1b, TNF-a, and IFN-g was significantly de-
creased in macrophage-depleted NOD mice as compared
with PBS-treated control NOD mice. These cytokines,
which are released from activated macrophages, are be-
lieved to be toxic to b cells (47–50). The toxic effect pro-
duced by activated macrophages on b cells is thought to be
mediated by the superoxide anion and hydrogen peroxide.
The b cell is very sensitive to the production of free radi-
cals because islet cells exhibit very low free radical scaveng-
ing activity (51, 52). Cytokines produced by islet-infiltrating
macrophages may contribute to b cell damage by inducing
the production of oxygen free radicals in the islets (53, 54).
Our recent studies have shown that the viral infection of b
cells results in the recruitment of macrophages into the pan-
creatic islets, and that the soluble mediators IL-1b, TNF-a,
and inducible nitric oxide synthase, known to be major fac-
tors produced by activated macrophages, contribute to the
destruction of b cells (55). Therefore, we cannot exclude
the possibility that the downregulation of these macro-
phage-derived soluble mediators also may play a role in the
protection of b cells in macrophage-depleted NOD mice.
A role of macrophages is the processing and presentation
of antigens to CD41 helper T cells in association with
MHC class II molecules (56, 57). Activation of CD41 T
cells can be through the processing and presentation of anti-
gens by APCs. Therefore, the sixth question posed in this
study was whether depletion of macrophages would affect
the antigen-presenting function in NOD mice. We mea-
sured the T cell proliferation response to islet antigens and
GAD (a well-known b cell autoantigen) in the presence of
splenocytes, as APCs, from macrophage-depleted or control
NOD mice. We found that the T cell proliferation response
was significantly decreased when we used splenocytes from
macrophage-depleted NOD mice as APCs. This result sug-
gests that the depletion of macrophages results in the down-
regulation of antigen-specific CD41 T cell activation.
Recent studies have shown that activated CD81 T cells
are capable of performing cytotoxic functions through the
use of perforin and granzymes as well as by the induction of
apoptosis through Fas–FasL interactions. Perforin-deficient
NOD mice showed a significantly decreased incidence of
diabetes and a delayed onset of the disease (58). In addition,
NODlpr/lpr mice, in which Fas is not expressed, do not de-
velop diabetes or insulitis (59, 60). Thus, the final question
put forth in this study was whether the depletion of mac-
rophages would influence the level of T cell activation. We
determined the level of expression of FasL and perforin in
splenic T cells from macrophage-depleted NOD mice. We
found that there was a significant decrease in the expression
of FasL and perforin in splenic T cells from lip-Cl2MDP–
treated NOD mice as compared with PBS-treated controls.
These results suggest that macrophages are required for the
activation of the cytotoxic T cells that can destroy pancre-
atic b cells. The precise mechanism for the involvement of
macrophages in T cell activation is not known. The IL-12
secreted by macrophages could activate Th1-type CD41 T
cells, and subsequently, the IL-2 and IFN-g produced by
these activated CD41 T cells may help with the maximal
activation of CD81 T cells. The downregulation of islet
cell–specific T cell activation may be another major factor
contributing to the impairment of the capability of T cells
to kill b cells in macrophage-depleted NOD mice.
In conclusion, macrophages are primary contributors to
the creation of the immune environment for the develop-
ment and activation of cytotoxic T cells that destroy pan-
creatic b cells, resulting in the development of autoim-
mune diabetes in NOD mice.357 Jun et al.
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